HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

The efficacy of 500 CentiGray radiation in the prevention of heterotopic ossification after total hip arthroplasty: a prospective, randomized, pilot study.

Abstract
A prospective, randomized, pilot study comparing 500 cGy (group A) versus 1,000 cGy (group B) radiation treatment for the prevention of heterotopic bone in a consecutive group of high-risk patients undergoing total hip arthroplasty was performed. Treatment was initiated within ninety-six hours and given in equal, divided doses: 2 doses for group A and 5 doses for group B. No statistically significant difference was found in the demographics between the 2 groups. At follow-up evaluation, the distribution of heterotopic bone according to the Brooker classification was: group A, 9 class 0, 17 class 1, one class 2, and 2 class 3. Group B: 17 class 0, 10 class 1, 2 class 2, and one class 3. This difference was not statistically significant (P=.086). Only 3 cases were considered treatment failures, for a success rate of 93% in group A and 97% in group B. As a result of this pilot study, 500 cGy radiation treatment appears to be effective in the prevention of clinically significant heterotopic ossification after total hip arthroplasty.
AuthorsDouglas E Padgett, Keith G Holley, Marilyn Cummings, Aaron G Rosenberg, Dale R Sumner, Dean Conterato, Jorge O Galante
JournalThe Journal of arthroplasty (J Arthroplasty) Vol. 18 Issue 6 Pg. 677-86 (Sep 2003) ISSN: 0883-5403 [Print] United States
PMID14513439 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial)
Topics
  • Adult
  • Aged
  • Arthroplasty, Replacement, Hip (adverse effects)
  • Chi-Square Distribution
  • Female
  • Humans
  • Male
  • Middle Aged
  • Ossification, Heterotopic (diagnostic imaging, etiology, prevention & control, radiotherapy)
  • Pilot Projects
  • Prospective Studies
  • Radiography
  • Radiotherapy Dosage
  • Risk Factors
  • Statistics, Nonparametric
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: